ReviewMicrobial biotechnology2017
Characteristics of the Clostridium difficile cell envelope and its importance in therapeutics.
Review in Microbial biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 69 citations in OpenAlex.
- Review
- Clostridioides difficile pathogenesis and control.Nature reviews. Microbiology · 2026Review
- Structural determinants of SlpA-mediated phage recognition in Clostridioides difficile.PLoS pathogens · 2025Article
- Analysis of essential genes inJournal of bacteriology · 2025Article
- Effect of rubusoside, a natural sucrose substitute, on the metabolism of Scardovia wiggsiae: a novel potential cariogenic pathogen.BMC biology · 2025Article
- Analysis of Essential Genes inbioRxiv : the preprint server for biology · 2025Article
- AgainstToxins · 2025Review
- Identification of two glycosyltransferases required for synthesis of membrane glycolipids inmBio · 2025Article
- Identification of two glycosyltransferases required for synthesis of membrane glycolipids inbioRxiv : the preprint server for biology · 2025Article
- Bioinformatic and experimental identification and characterization ofFrontiers in immunology · 2025Article
- Whole-genome sequencing of toxigenic Clostridioides difficile reveals multidrug resistance and virulence genes in strains of environmental and animal origin.BMC veterinary research · 2024Article
- Atomic structures of a bacteriocin targeting Gram-positive bacteria.Nature communications · 2024Article
- Emerging Diagnostics inInternational journal of molecular sciences · 2024Review
- Revealing roles of S-layer protein (SlpA) inMicrobiology spectrum · 2024Article
- Atomic structures of a bacteriocin targeting Gram-positive bacteria.Research square · 2024Article
- Unraveling Physical Interactions of Clostridioides difficile with Phage and Phage-Derived Proteins Using In Vitro and Whole-Cell Assays.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Review
- Mucosal Vaccination Strategies againstVaccines · 2023Review
- Non-Toxin-BasedPathogens (Basel, Switzerland) · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Clostridium difficile infection (CDI) is a challenging threat to human health. Infections occur after disruption of the normal microbiota, most commonly through the use of antibiotics. Current treatment for CDI largely relies on the broad-spectrum antibiotics vancomycin and metronidazole that further disrupt the microbiota resulting in frequent recurrence, highlighting the need for C. difficile-specific antimicrobials. The cell surface of C. difficile represents a promising target for the development of new drugs. C. difficile possesses a highly deacetylated peptidoglycan cell wall containing unique secondary cell wall polymers. Bound to the cell wall is an essential S-layer, formed of SlpA and decorated with an additional 28 related proteins. In addition to the S-layer, many other cell surface proteins have been identified, including several with roles in host colonization. This review aims to summarize our current understanding of these different C. difficile cell surface components and their viability as therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.